SS Innovations Reports 79% Growth in SSi Mantra Procedures, Expands Global Reach

SS Innovations International (NASDAQ: SSII) has reported significant growth in the utilization and global footprint of its SSi Mantra surgical robotic system. As of September 8, 2026, the company has achieved 14,103 cumulative procedures, a 79% increase from 7,885 at the end of 2025. The installed base of SSi Mantra systems has also expanded by 42%, reaching 238 units compared to 168 previously. This growth matters because it demonstrates accelerating adoption of a cost-effective robotic surgery platform, potentially broadening access to advanced surgical care in underserved regions.

The SSi Mantra is now installed in 12 countries, with approximately 1,500 physicians trained on the system. It has been used for more than 170 types of surgical procedures, underscoring its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company's success in penetrating diverse markets and addressing a wide range of surgical needs, which could translate into improved patient outcomes and operational efficiencies for healthcare providers.

SS Innovations also emphasized its progress in pediatric and telesurgery applications. As of August 31, the company reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India. Such achievements are important because they showcase the system's reliability and its potential to facilitate remote surgical care, which is crucial for patients in remote or underserved areas.

Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. Additionally, SS Innovations believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are critical as they would open up two of the largest healthcare markets, significantly expanding the company's addressable market and competitive positioning. For investors, the successful clearance could drive substantial revenue growth and validate the technology's safety and efficacy.

For more details, the full report can be accessed at https://ibn.fm/DJILj. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. Full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN are available at https://IBN.ai/Disclaimer.